Vistagen Faces Class Action Lawsuit Over Failed Trial, Stock Crashes 80%
Class action lawsuit filed against Vistagen Therapeutics after Phase 3 trial failure causes 80% stock plunge. Investors have until March 16, 2026 deadline.
VTGNclass action lawsuitmisleading statements